Inclusion Criteria:

• History of type 2 diabetes
• HbA1c between 7% to 10% at screening visit
• Treatment with metformin only with a fixed and stable dose of 1500 mg/day or more for at least the past 3 months prior to screening visit

Exclusion Criteria:

• Within 3 months prior to screening visit: change in lipid modifying agent, administration of systemic corticosteroids for more than 10 days, use of any anti-obesity agent or drugs for weight loss
• Weight loss of more than 5 kg within 3 months prior to screening
• Administration of other investigational drugs within 30 days prior to screening visit
• Prior exposure to CB1 antagonists including rimonabant
• Presence or history of cancer within the past five years
• Pregnant or breast-feeding women
• Presence of any severe medical or psychological condition that, in the opinion of the investigator, would compromise the patient's safe participation including uncontrolled serious psychiatric illness such a major depression within the last 2 years, and history of other severe psychiatric disorders.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.